Tag Archives: kidney failure prevention

Risks of Kidney Function Decline After Kidney Donation and Post-Donation Management Guide

Living kidney donation is one of the most effective treatments for patients with chronic kidney disease. A recent study in New Zealand has confirmed that the long-term risk of kidney failure, cardiovascular disease, and complications following kidney donation is very low. This article discusses the characteristics of suitable kidney donors and the best practices for post-donation health management.


Who Is a Suitable Kidney Donor?

  • Healthy adults with normal kidney function
  • Individuals without chronic diseases such as hypertension or diabetes
  • People with sufficient renal cortical volume

Meeting these conditions helps maintain kidney function more effectively after donation.


Summary of Kidney Donor Health Management

Kidney donors should follow these guidelines to maintain good health post-donation:

  • Regular health check-ups to monitor kidney function
  • Maintaining a low-sodium and balanced diet
  • Engaging in consistent aerobic exercise and weight management
  • Closely monitoring blood pressure and blood sugar levels
  • Utilizing specialized kidney donor clinics for continuous medical support

Kidney donor clinics provide long-term, specialized medical care, including pre- and post-surgery health management and psychosocial support to ensure donor well-being.


New Zealand Study Methods

The New Zealand research team collected and analyzed long-term health data from 1,339 kidney donors between 1988 and 2018. The primary objectives were to assess the incidence of kidney failure, mortality rates, cardiovascular disease (CVD), and acute complications within 90 days post-surgery. Data was sourced from the New Zealand Ministry of Health (MoH), hospital records, and ANZDATA to ensure accuracy.


New Zealand Study Results

  • Kidney failure incidence: Only 5 donors (0.4%) developed kidney failure, equivalent to 3 per 10,000 person-years.
  • Primary causes of kidney failure: Diabetic kidney disease (4 cases), glomerulonephritis (1 case).
  • Mortality rates: 10-year survival rate was 99%, and 30-year survival rate was 88.7%, comparable to or better than the general population.
  • CVD incidence: 11.6 per 10,000 person-years, slightly higher in men.
  • Postoperative complications: 22% experienced complications, but severe cases were below 5%.


Conclusion and Implications of the New Zealand Study

Long-term health risks for kidney donors are very low. However, individuals with diabetes or hypertension should be more cautious. Regular post-donation monitoring and proper management are crucial for maintaining optimal health.


Brief Overview of Related Studies in Korea and Abroad

Similar findings have been reported in Korea, the United States, and Europe. Studies suggest that structured kidney donor clinics significantly reduce the risk of kidney function decline after donation.


Conclusion

Appropriate donor selection and continuous health management programs effectively mitigate the risk of kidney function decline after donation. Regular health check-ups and a healthy lifestyle are essential for kidney donors to maintain long-term well-being.


Focus Keyphrase: Kidney function decline after donation

Meta Description: An in-depth look at the risks of kidney function decline after kidney donation and best practices for post-donation health management.

Tags: kidney donation, kidney function decline, donor health management, kidney failure prevention, kidney transplant


Reference:

  • Chan et al. (2025), Outcomes of Living Kidney Donors Following Donor Nephrectomy in Aotearoa New Zealand. Kidney International Reports.

Micronutrient Management in Kidney Disease Patients: Risks of Deficiency and Overconsumption

Semaglutide kidney protection– True or Illusion?

1. What is Semaglutide?

Semaglutide kidney protection, Semaglutide is a GLP-1 (Glucagon-Like Peptide-1) receptor agonist originally developed for type 2 diabetes treatment. However, recent clinical trials indicate that it may also have cardiovascular and kidney-protective benefits, drawing significant attention in nephrology and endocrinology.

Common semaglutide-based medications include Ozempic and Wegovy, widely prescribed for both diabetes management and obesity treatment.


2. Semaglutide’s Kidney Protective Effects: Scientific Evidence

The FLOW (Evaluate Renal Function With Semaglutide Once Weekly) trial investigated semaglutide’s impact on chronic kidney disease progression in diabetic patients. The key findings were:

Reduced Risk of Kidney Failure

  • Semaglutide reduced the risk of kidney failure by 24%
  • Hazard ratio (HR): 0.76 (95% CI: 0.66–0.88, p = 0.0003)

Slower Decline in eGFR (Estimated Glomerular Filtration Rate)

  • Placebo group: -3.36 ml/min/1.73㎡ per year
  • Semaglutide group: -2.19 ml/min/1.73㎡ per year

Significant Weight Loss Observed

  • Average weight reduction of 4.1 kg (95% CI: 3.65–4.56 kg)

These results suggest that semaglutide may not only regulate blood sugar but also help slow kidney function decline.


3. Controversy: Is Kidney Protection an Illusion Caused by Weight Loss?

While these findings are promising, some researchers question whether semaglutide’s renal benefits are truly independent of its weight loss effects.

🔹 Weight Loss Can Artificially Improve eGFR Readings

  • Losing weight can temporarily increase eGFR measurements, making kidney function appear better than it actually is.
  • Thus, the reported improvements in eGFR might not reflect actual kidney protection but rather a calculation artifact.

🔹 The Study Did Not Fully Account for Weight Loss Effects

  • Since semaglutide induces weight loss, it is crucial to determine if kidney protection persists after adjusting for weight loss effects.
  • Further analysis is needed to separate true renal benefits from weight-related changes.

4. Future Research Directions and Key Questions

1️⃣ Does semaglutide’s kidney protection occur independently of weight loss?
➡️ Further studies should analyze kidney function changes after adjusting for weight loss effects.

2️⃣ How can we rule out weight-related measurement biases?
➡️ Researchers should compare kidney function data before and after removing body surface area indexing from eGFR calculations.

3️⃣ Do non-obese patients experience the same kidney benefits?
➡️ If semaglutide truly protects the kidneys, its benefits should also be observed in patients without obesity.


5. Could Semaglutide Become a Kidney Protection Therapy?

At present, semaglutide shows strong potential as a kidney-protective agent. However, further studies are essential to confirm whether its benefits are genuine or mainly driven by weight loss.

📌 What We Know So Far
✔️ Semaglutide may reduce the risk of kidney failure.
✔️ It slows eGFR decline in patients with CKD.
✔️ Weight loss might play a significant role in the observed benefits.

📌 Remaining Uncertainties
⚠️ eGFR improvements may be overestimated due to weight loss effects.
⚠️ More research is needed to confirm benefits in non-obese individuals.
⚠️ Long-term studies should evaluate true kidney protection beyond weight effects.


Conclusion: Semaglutide kidney protection?

Semaglutide presents exciting possibilities for kidney protection, but additional studies must clarify whether its effects are direct or weight loss-related. As research progresses, we will gain deeper insights into its true potential in CKD management.


The Risks and Management of Hypertension: If Family History